Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Stull SM"'
Autor:
Jaeger-Ruckstuhl CA; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Electronic address: cjaeger@fredhutch.org., Lo Y; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Fulton E; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Waltner OG; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Shabaneh TB; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Simon S; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Muthuraman PV; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Correnti CE; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Newsom OJ; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Engstrom IA; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Kanaan SB; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Bhise SS; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Peralta JMC; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Ruff R; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Seattle Children's Hospital, Seattle, WA 98105, USA., Price JP; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Seattle Children's Hospital, Seattle, WA 98105, USA., Stull SM; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Stevens AR; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Bugos G; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Kluesner MG; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Voillet V; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Muhunthan V; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Morrish F; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Olson JM; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Seattle Children's Hospital, Seattle, WA 98105, USA., Gottardo R; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Department of Statistics, University of Washington, Seattle, WA 98195, USA; Swiss Institute of Bioinformatics, University of Lausanne and Lausanne University Hospital, Lausanne 1011, Switzerland., Sarthy JF; Seattle Children's Hospital, Seattle, WA 98105, USA; Basic Science Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Henikoff S; Basic Science Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Howard Hughes Medical Institute, Seattle, WA 98195, USA., Sullivan LB; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Furlan SN; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Seattle Children's Hospital, Seattle, WA 98105, USA., Riddell SR; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Department of Medicine, University of Washington, Seattle, WA 98195, USA. Electronic address: sriddell@fredhutch.org.
Publikováno v:
Immunity [Immunity] 2024 Feb 13; Vol. 57 (2), pp. 287-302.e12.
Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity.
Autor:
Shabaneh TB; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Stevens AR; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Stull SM; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Shimp KR; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Seaton BW; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Gad EA; Comparative Medicine, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Jaeger-Ruckstuhl CA; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Simon S; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Koehne AL; Experimental Histopathology, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Price JP; Molecular Design and Therapeutics, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Olson JM; Molecular Design and Therapeutics, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Hoffstrom BG; Antibody Technology, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Jellyman D; Antibody Technology, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Riddell SR; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA sriddell@fredhutch.org.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Feb 07; Vol. 12 (2). Date of Electronic Publication: 2024 Feb 07.
Autor:
Leung I; Clinical Research Division, Fred Hutchinson Research Center, Seattle, WA., Templeton ML; Clinical Research Division, Fred Hutchinson Research Center, Seattle, WA., Lo Y; Clinical Research Division, Fred Hutchinson Research Center, Seattle, WA., Rajan A; Clinical Research Division, Fred Hutchinson Research Center, Seattle, WA., Stull SM; Clinical Research Division, Fred Hutchinson Research Center, Seattle, WA., Garrison SM; Clinical Research Division, Fred Hutchinson Research Center, Seattle, WA., Salter AI; Clinical Research Division, Fred Hutchinson Research Center, Seattle, WA., Smythe KS; Clinical Research Division, Fred Hutchinson Research Center, Seattle, WA., Correnti CE; Clinical Research Division, Fred Hutchinson Research Center, Seattle, WA., Srivastava S; Clinical Research Division, Fred Hutchinson Research Center, Seattle, WA., Yeung CCS; Clinical Research Division, Fred Hutchinson Research Center, Seattle, WA.; Department of Pathology, University of Washington, Seattle, WA., Riddell SR; Clinical Research Division, Fred Hutchinson Research Center, Seattle, WA.; School of Medicine, University of Washington, Seattle, WA.
Publikováno v:
Blood advances [Blood Adv] 2023 Jun 27; Vol. 7 (12), pp. 2718-2730.
Autor:
Wilkens AB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Molecular and Cellular Biology, University of Washington, Seattle, WA., Fulton EC; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Pont MJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Cole GO; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Leung I; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Stull SM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Hart MR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Bernstein ID; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Furlan SN; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Riddell SR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Molecular and Cellular Biology, University of Washington, Seattle, WA.
Publikováno v:
Blood [Blood] 2022 Nov 24; Vol. 140 (21), pp. 2261-2275.
Autor:
Shabaneh TB; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA, United States., Moffett HF; Outpace Bio, Inc., Seattle, WA, United States., Stull SM; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA, United States., Derezes T; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA, United States., Tait LJ; Outpace Bio, Inc., Seattle, WA, United States., Park S; Lyell Immunopharma, Inc., Seattle, WA, United States., Riddell SR; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA, United States., Lajoie MJ; Outpace Bio, Inc., Seattle, WA, United States.
Publikováno v:
Frontiers in molecular medicine [Front Mol Med] 2022 Oct 11; Vol. 2, pp. 1026474. Date of Electronic Publication: 2022 Oct 11 (Print Publication: 2022).
Autor:
Veatch JR; Clinical Research Division and Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, USA.; Department of Medicine, University of Washington, Seattle, Washington, USA., Singhi N; Clinical Research Division and Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, USA., Srivastava S; Clinical Research Division and Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, USA., Szeto JL; Clinical Research Division and Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, USA., Jesernig B; Clinical Research Division and Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, USA., Stull SM; Clinical Research Division and Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, USA., Fitzgibbon M; Public Health Sciences Division, FHCRC, Seattle, Washington, USA., Sarvothama M; Clinical Research Division and Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, USA., Yechan-Gunja S; Clinical Research Division and Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, USA., James SE; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Riddell SR; Clinical Research Division and Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, USA.; Department of Medicine, University of Washington, Seattle, Washington, USA.
Publikováno v:
The Journal of clinical investigation [J Clin Invest] 2021 Aug 16; Vol. 131 (16).
Autor:
Mei L; Department of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona 85721, United States., Moutet J; Department of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona 85721, United States., Stull SM; Department of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona 85721, United States., Gianetti TL; Department of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona 85721, United States.
Publikováno v:
The Journal of organic chemistry [J Org Chem] 2021 Aug 06; Vol. 86 (15), pp. 10640-10653. Date of Electronic Publication: 2021 Jul 13.